Prosecution Insights
Last updated: April 19, 2026
Application No. 17/891,234

BIODEGRADABLE GRAFT POLYMERS

Final Rejection §103
Filed
Aug 19, 2022
Examiner
LISTVOYB, GREGORY
Art Unit
1765
Tech Center
1700 — Chemical & Materials Engineering
Assignee
The Procter & Gamble Company
OA Round
2 (Final)
67%
Grant Probability
Favorable
3-4
OA Rounds
3y 2m
To Grant
96%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allow Rate
798 granted / 1195 resolved
+1.8% vs TC avg
Strong +30% interview lift
Without
With
+29.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
39 currently pending
Career history
1234
Total Applications
across all art units

Statute-Specific Performance

§101
0.1%
-39.9% vs TC avg
§103
57.7%
+17.7% vs TC avg
§102
20.4%
-19.6% vs TC avg
§112
6.6%
-33.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1195 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . The previous prior art rejection under Ebert et al (US 20160222160) in view of Boeckh et al (US 6156720) and Bodet et al (US 6710023) maintained and therefore it is proper to make this rejection FINAL. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1 and 5-10 are rejected under 35 U.S.C. 103 as being unpatentable over Ebert et al (US 20160222160) in view of Boeckh et al (US 6156720). Claims 1-10 are rejected under 35 U.S.C. 103 as being unpatentable over Bodet et al (US 6710023). The rejection can be found in the NON-FINAL office action mailed 9/15/2025 and is herein incorporated by reference Response to Arguments Applicant's arguments filed 12/15/2025 have been fully considered but they are not persuasive. Applicant argues that Ebert's alkylenoxy units are being predominantly ethylene oxide units , while Boeckh discloses a different pattern of EO and propoxylation ("PO") incorporation. Examiner addressed this issue in previous Office Action. In particular, Examiner acknowledged that Ebert (US 20160222160) does not teach that R1 represents predominantly C3-C4 alkylene units and it was the sole reason for modification of the primary reference above with Boeckh et al (US 6156720). Boeckh discloses that his composition has an excellent resistance to an oxidative bleaching agent due to its higher hydrophobicity (see 1:30). In other word, the reference favors the replacement of polyethylene oxide units with more hydrophobic polypropylene oxide ones. Therefore, it would have been obvious to person of ordinary skills in the art to use more hydrophobic dispersant with higher ratio of propylene oxide units in laundry process in order to increase its resistance to oxidative bleaching. (see Non-Final Office Action issued on 9/15/2025). Applicant argues that Bodet et al (US 6710023) disclosure is not specific enough. Examiner disagrees. The reference discloses all the elements of the claimed structure. A genus does not always anticipate a claim to a species within the genus. However, when the species is clearly named, the species claim is anticipated no matter how many other species are additionally named. Ex parte A, 17 USPQ2d 1716 (Bd. Pat. App. & Inter. 1990) See also MPEP 2131.02 Therefore, it would have been obvious to person of ordinary skills in the art to use cycloalkylenes in Bodet's formula, since they clearly named in the reference (see Non-Final Office Action issued on 9/15/2025). . Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GREGORY LISTVOYB whose telephone number is (571)272-6105. The examiner can normally be reached 9am-5pm EST M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heidi Riviere Kelley can be reached at (571) 270-1831. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. GL /GREGORY LISTVOYB/Primary Examiner, Art Unit 1765
Read full office action

Prosecution Timeline

Aug 19, 2022
Application Filed
Sep 11, 2025
Non-Final Rejection — §103
Dec 15, 2025
Response Filed
Feb 27, 2026
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12590182
POLYPHENYLENE ETHER MELT EXTRUSION FORMED BODY AND METHOD FOR PRODUCING POLYPHENYLENE ETHER MELT EXTRUSION FORMED BODY
2y 5m to grant Granted Mar 31, 2026
Patent 12590184
POLYIMIDE RESIN MOLDED BODY AND PRODUCTION METHOD FOR SAME
2y 5m to grant Granted Mar 31, 2026
Patent 12583987
SURFACE MODIFYING COMPOSITION, MODIFIED PRODUCT, AND METHOD OF PRODUCING MODIFIED PRODUCT
2y 5m to grant Granted Mar 24, 2026
Patent 12583974
POLYAMIDE-IMIDE-BASED FILM, PREPARATION METHOD THEREOF, AND COVER WINDOW AND DISPLAY DEVICE COMPRISING THE SAME
2y 5m to grant Granted Mar 24, 2026
Patent 12583983
POLYIMIDE FILM HAVING HIGH DIMENSIONAL STABILITY, AND METHOD FOR MANUFACTURING SAME
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
67%
Grant Probability
96%
With Interview (+29.7%)
3y 2m
Median Time to Grant
Moderate
PTA Risk
Based on 1195 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month